CSSi LifeSciences Announces Strategic Partnership with Australian States to Facilitate Entry into the US Healthcare Market



CSSi LifeSciences, a leading global provider of regulatory affairs and US healthcare market access, is proud to announce a groundbreaking partnership with the governments of New South Wales, Queensland, and Victoria, three prominent Australian states. This collaboration is designed to offer comprehensive support to Australian life science companies seeking entry into the highly dynamic US healthcare market.

The focal point of this partnership is the annual 2024 CSSi LifeSciences Partnering Forum, an exclusive partnering event aimed at fostering collaboration, knowledge sharing, and strategic alliances. The Forum provides a unique platform for Australian life science companies to connect with key stakeholders, including strategic investors, life science service providers, and decision-makers. It also provides an opportunity for Australian companies to gain insights into the intricacies of the US healthcare market. Attendees will have the chance to explore non-dilutive funding and partnership possibilities with prestigious institutions such as the National Institutes of Health, US Department of Defense, US FDA, and the National Cancer Institute. This year’s event will take place during the JPM Healthcare Week at the Hilton Union Square in San Francisco.

Key highlights of the Partnering Forum include morning plenary sessions covering crucial topics ranging from the US investor outlook in 2024 to intellectual property considerations, regulatory approval pathways through the US FDA, and the establishment of a strategic operational base in the US. In a collaborative effort with the Australian states, CSSi LifeSciences will co-host a special session titled “Why Australia for Clinical Trials”. This session aims to showcase Australia’s strengths and advantages as a destination for clinical trials, fostering stronger ties between the two nations in the life science sector.

CSSi LifeSciences is excited about the potential impact of this partnership in enhancing bilateral relations between the United States and Australia within the life science industry. The Forum represents a significant step forward in promoting global collaboration and fostering innovation in healthcare.

“We are thrilled to embark on this journey with the governments of New South Wales, Queensland, and Victoria. This partnership underscores our commitment to supporting the global life science community and facilitating the entry of Australian companies into the US healthcare market,” said Jim Sergi, President at CSSi LifeSciences.

For media inquiries or further information, please contact:

Ernesto Chanona
VP, Business Development & Government Affairs

About CSSi LifeSciences

CSSi LifeSciences is a global, innovative CRO and consulting group. We specialize in advancing therapeutics and medical devices through development and regulatory approval. We offer customized solutions that mitigate risk, time, and expense to support the U.S. market goals of your company.